Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
 
Sponsors and Collaborators

AVAX Technologies
 
Contact
United States, Illinois
Julio D Doligosa
847-872-4019
[email protected]

United States, Oklahoma
Sharrese Bishop, RN,BSN,CCRC
918-286-5898
[email protected]


Continue Reading

United States, Pennsylvania
Marty Weinar, MS, RN, CAGS
215-537-7569
[email protected]

 
Principal Investigators
Henry E Schea
AVAX Technologies
 
ClinicalTrials.gov Identifier
NCT00660101